Cellyan Biotechnology Co., Ltd (HKPD)
NASDAQ: HKPD · Real-Time Price · USD
0.7990
+0.0160 (2.04%)
At close: Feb 13, 2026, 4:00 PM EST
0.7760
-0.0230 (-2.88%)
After-hours: Feb 13, 2026, 6:16 PM EST
Cellyan Biotechnology Revenue
In the fiscal year ending March 31, 2025, Cellyan Biotechnology had annual revenue of $20.31M with 21.72% growth. Cellyan Biotechnology had revenue of $9.22M in the half year ending March 31, 2025.
Revenue (ttm)
$20.31M
Revenue Growth
+21.72%
P/S Ratio
0.40
Revenue / Employee
$752,364
Employees
27
Market Cap
8.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 20.31M | 3.63M | 21.72% |
| Mar 31, 2024 | 16.69M | 4.13M | 32.91% |
| Mar 31, 2023 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHKPD News
- 4 weeks ago - Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - GlobeNewsWire
- 2 months ago - Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 2 months ago - DCS Announces Q3 2025 Quarterly Financial Statements - Newsfile Corp
- 11 months ago - Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024 - PRNewsWire
- 1 year ago - U.S. IPO Weekly Recap: Oil And Gas Well Equipment Provider Flowco Debuts, While More Sizable Deals Join The Pipeline - Seeking Alpha
- 1 year ago - Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering - PRNewsWire